What is Protagonist Therapeutics's G&A?

Protagonist Therapeutics (PTGX) reported G&A of $13.28M in Q1 2026.

How has Protagonist Therapeutics's G&A changed year-over-year?

Protagonist Therapeutics's G&A increased by 13.1% year-over-year, from $11.74M to $13.28M.

What is the long-term trend for Protagonist Therapeutics's G&A?

Over 4 years (2021 to 2025), Protagonist Therapeutics's G&A has grown at a 13.3% compound annual growth rate (CAGR), from $27.2M to $44.85M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Protagonist Therapeutics PTGX G&A

G&A at other companies

Spyre Therapeutics, Inc.SYRE

$15.23M+27.5%

Summit TherapeuticsSMMT

$62.59M+302%

Apogee Therapeutics, Inc.APGE

——

Kymera TherapeuticsKYMR

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's G&A?: Protagonist Therapeutics (PTGX) reported G&A of $13.28M in Q1 2026.
How has Protagonist Therapeutics's G&A changed year-over-year?: Protagonist Therapeutics's G&A increased by 13.1% year-over-year, from $11.74M to $13.28M.
What is the long-term trend for Protagonist Therapeutics's G&A?: Over 4 years (2021 to 2025), Protagonist Therapeutics's G&A has grown at a 13.3% compound annual growth rate (CAGR), from $27.2M to $44.85M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.